Moreshwar S. Desai, MD

Dr. Desai is interested in the molecular mechanisms of cardiac dysfunction in cirrhotic liver diseases. Along with his mentor, Dr. Saul Karpen, he has shown a new form of cardiomyopathy in infants and children with end stage cirrhotic liver disease secondary to biliary atresia and have shown that abnormal cardiac function in these infants affects post-transplant hospital and ICU length of stay. They have also reproduced key features of cardiomyopathy seen in clinical practice in novel mouse models of cholestasis and liver injury in an attempt to understand the pathophysiology and molecular mechanisms of cardiac dysfunction, termed- Cirrhotic Cardiomyopathy. Dr. Desai has successfully finished a project looking at the role of TLR4 and TLR2 in steatohepatitis with atherogenic diet.

Educacion

Organizaciones

* Texas Children’s Hospital physicians’ licenses and credentials are reviewed prior to practicing at any of our facilities. Sections titled From the Doctor, Professional Organizations and Publications were provided by the physician’s office and were not verified by Texas Children’s Hospital.

Xu Z, Desai M, Philip J, Sivsubramanian N, Bowles NE, Vallejo JG. Conditional transgenic expression of TIR-domain-containing adaptor-inducing interferon-? (TRIF) in the adult mouse heart is protective in acute viral myocarditis. Basic Research in Cardiology 2011 Sept 29 (Epub ahead of print) PMID: 21956162.

View VIICTR Publications:

https://profiles.viictr.org/display/BCM/moreshwar-desai